By Berger Montague

PHILADELPHIA , Sept. 25, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) after a class action lawsuit was filed against Altimmune.

Investor Deadline: Investors who purchased or acquired Altimmune securities between August 10, 2023 through June 25, 2025 (the "Class Period") may, no later than October 6, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE .

On June 26, 2025, Altimmune

See Full Page